|
|
Thank
you to our
sponsors. |
|
|
|
Founded
in 2004, BioStrategy Partners is a virtual
incubator providing technology and business
development services to emerging-stage life
sciences companies and university-based research
projects in the Greater Philadelphia
region. BioSP specializes in offering
business guidance and support to first-time
entrepreneurs, scientific founders, and
university-based principal
investigators. For more information,
please visit our web site, http://www.biostrategypartners.org. |
|
|
|
From
the Executive
Director
|
|
BioSP
is currently recruiting for our Fall Life Sciences
Leadership Forum. These twice-monthly
breakfast workshops are designed to boost business
acumen while networking participants into the
broader life sciences community.
Expert presenters will provide practical guidance
and insights into the following
topics:
- The
Building Blocks to Growing Your Business
- Strategy
and Risk in Building a Business Plan
- Funding
Options: Grants
- FIRE:
What you need to know about Finance, Insurance
and Real Estate
- Fundamentals
of Marketing and Communication
- The
How-To's of Business Presentations
- Final
Presentations (to a panel of experts for
feedback)
Sessions
are specifically geared to pre-seed life sciences
companies headed by scientific founders and/or
first-time entrepreneurs. There is no charge
to attend but we do require an interview and a
commitment to attend all seven sessions.
The
Fall Life Sciences Leadership Forum is made
possible by an Innovation Investment Grant from
the Delaware Valley Innovation
Network.
|
|
Fox
Chase Cancer Center
Launches Institute for
Personalized Medicine |
|
In
an important step towards personalized cancer
treatment, Fox Chase Cancer Center has
launched the Institute for Personalized Medicine,
a program that will aim to match emerging targeted
drug therapies to the unique genetic profiles of
individual patient tumors on a much larger scale
than previously possible. The goal of the new
Institute is to make the one-size-fits-all
approach to cancer treatment that dominates care
today a thing of the
past.
"What
we think of as personalized medicine is already
practiced to great effect with a tiny handful of
therapeutics in certain cancers, but the Institute
for Personalized Medicine has the potential to
expand dramatically both the pool of available
drugs and the list of eligible cancer types," says
Jeff Boyd, Ph.D., Fox Chase's chief scientific
officer. "With its proven expertise in cancer
genetics and the conduct of clinical trials, Fox
Chase is uniquely poised to drive this
transformation."
"Within
ten years, this will be the standard of care for
treating cancer of all types, but today you will
find it at Fox Chase," Boyd
says.
|
|
News
From Our Community |
|
BioStrategy
Partners' Board member, Charlie
Huntington,
of the Huntington/Kraus
Financial Group of Wells Fargo Advisors,
was awarded the
American Heart Association's Distinguished
Achievement Award for 2008-2009 from the Great
Rivers Affiliate Leadership Development Committee
serving Delaware,
Kentucky,
Ohio, Pennsylvania and West
Virginia.
This
award recognizes an individual who has contributed
significantly to the success of the Great Rivers
Affiliate, honoring an individual for exceptional
and outstanding contributions to the advancement
of the American Red Cross'
mission.
The
BioAnalytics Group LLC ww.bioanalyticsgroup.com and
Brighter Ideas,
Inc. www.brighterideasinc.com have
signed a collaboration agreement to focus on
development of technologies for analyzing
proteins, protein inhibitors, and their activities
in mixtures. The work is expected to lead to
commercialized products for the research,
diagnostics, and therapeutic
industries.
"We've
been seeking partnerships with organizations
developing new biomedical assay technologies,"
says G. Scott Lett, Ph.D., CEO of The BioAnalytics
Group. "Brighter Ideas is working to commercialize
their fluorescent protein technologies. The
marriage of our data analysis and software
development experience with their industry-leading
expertise has created a wonderful collaborative
opportunity."
Since
its founding in 2003, Brighter Ideas, Inc. has
focused on fluorescent protein chemistry, leading
to novel assay development. "BioAnalytics is a
progressive company that will provide additional
value and commercial viability to
| | |
